-
Healthcare
-

The Palantir Contract Was Meant To Prove The Case For Itself. Instead It Has Produced A Governance Problem The Next Government Cannot Ignore

By
Distilled Post Editorial Team

When health service data staff write anonymously to a cabinet minister warning that the systems built to protect patients are instead eroding the trust that makes those systems work, something has shifted beyond the normal friction of a difficult public contract. That is where the Palantir dispute now sits. The health and social care select committee's call this week for the government to abandon the £330m federated data platform contract did not arrive as an isolated complaint. It followed a similar verdict from the science and technology committee last month, itself following months of internal warnings from NHS technologists that patient privacy protections were inadequate and that clinical trust in the platform was already deteriorating. What began as a contested claim about software performance has become a question about whether the government can keep defending a data infrastructure decision purely through delivery statistics while the institutions meant to hold it accountable, and the staff meant to operate it, converge on the opposite conclusion.

The department's position has not changed since the criticism began. Ministers point to additional operations delivered, shorter discharge delays and faster cancer diagnosis confirmation as evidence the platform works as intended. Palantir's own defence follows the same logic, treating the argument as settled by outcome data and casting critics as prioritising ideology over patient safety. That framing might have held if the criticism were coming only from campaigners or opposition politicians with an obvious institutional grievance. It is harder to sustain when the criticism includes NHS data professionals themselves, speaking from inside the system the platform is supposed to serve, and when two parliamentary committees with different remits and different political compositions have independently reached the same recommendation.

This matters for how the incoming government approaches the February 2027 break clause, which now functions less as a routine contractual checkpoint and more as a forced decision point with genuine political weight attached. Continuing the contract without addressing the trust deficit invites the government to spend political capital defending a position that its own oversight structures no longer support. Exercising the break clause without a credible domestic alternative in place risks disrupting a data platform that, whatever its critics say about consent and control, is embedded in day to day clinical and operational processes across NHS trusts. Neither option is straightforward, and the department's insistence on litigating the dispute through activity metrics suggests it has not yet reckoned with the fact that the argument has moved past performance and into governance.

The Metropolitan Police's decision to walk away from a comparable Palantir contract, now being challenged in the High Court, adds a further complication. It establishes that a major public body can decline to proceed with Palantir on value grounds rather than technical failure, and that such a decision can survive legal challenges long enough to matter politically even before the litigation concludes. Other public institutions weighing similar contracts will be watching how that case resolves, and NHS leaders considering the platform's future will not be able to treat the Met's position as unrelated to their own.

The deeper risk for the NHS is not that the federated data platform fails on its own technical terms. It is that continued reliance on the platform, absent a credible plan to rebuild clinician and public confidence, degrades the quality of the data being fed into it. A system dependent on complete and trusted patient information cannot indefinitely absorb scepticism from the staff who populate that information without consequences for the data itself. Ministers can continue to answer critics with waiting list statistics for as long as the contract runs. What they cannot do, if the break clause decision is to hold any credibility, is treat the accumulating institutional judgment against Palantir as background noise rather than the central fact of the case.